Research Blogs
-
While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of cancer. In the early 2000s, EGFR was the first gene in non-small cell lung cancer (NSCLC) to be matched with a targeted therapy.
-
The Viral Triple Threat: COVID-19, Flu and RSV
It is hard to believe that we’re already in November and celebrating Lung Cancer Awareness Month! In addition to recognizing LCAM, fall is also a good time to remind people
-
The 2021 Global Lung Cancer Therapy Landscape
On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “ The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of
-
Dr. Charles Rudin discusses key highlights from ASCO 2022
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago June 3-7, 2022. Dr. Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, sat down with Dr. Charles Rudin to discuss key highlights from ASCO 2022 and what they mean for the lung cancer community.
-
The Importance of Health Disparities Research
In 2021, LUNGevity Foundation announced our inaugural Health Equity and Inclusiveness Workforce Development Awards to help combat the lack of diversity among lung cancer
-
KRAS: How It Started vs. How It’s Going
On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC).
-
Progress in Targeting MET Drivers in Advanced NSCLC
MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in
-
Studying Drug Resistance From a New Angle
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung
-
New Options in Adjuvant Therapy for Early-Stage NSCLC
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the
-
An Overview of Biomarker Testing
In recent years, biomarker testing has grown increasingly more important and more complex as researchers understand critical details about the molecular basis of lung cancer. By
-
Omicron: What We Know So Far and How You Can Stay Safe This Holiday Season
By now, you have probably heard the news that scientists have discovered a new variant of the virus that causes COVID-19. This one is called omicron, a letter in the Greek alphabet
-
Pulmonary Rehab for Lung Cancer
Some people with lung cancer have reduced lung function from their cancer or their treatments, like surgery, radiation, or chemotherapy. People with diminished lung functional